Arctoris has signed a Memorandum of
Understanding with listed Korean company Syntekabio, Inc. to collaborate on
drug discovery efforts. The first project under the agreement sees the two
companies work together to assess small molecule therapeutics for COVID-19.
The MoU brings together two highly
complementary technologies: Syntekabio is a leading AI-driven drug discovery
company that uses machine learning and supercomputing to discover new drugs, and
Arctoris is a British technology company that has developed a fully automated
drug discovery platform enabling rapid generation of high-quality drug
discovery data. Syntekabio will use Arctoris’ unique technology platform for
biochemical and cell-based experiments including target-based assays and
viability assessments.
Access to the Arctoris platform enables the
company’s clients and partners to conduct their drug discovery processes in
full automation. Available services include dataset generation for AI model
training and validation, hit-to-lead, lead optimisation and candidate
selection.
Under the terms of the MoU, Syntekabio and
Arctoris work together to identify and screen a series of potential candidate
molecules for COVID-19 treatment, not only saving development time, but also
ensuring a greater degree of confidence in the experimental results.
Martin-Immanuel Bittner MD DPhil, CEO of
Arctoris said: “This partnership
highlights the utility and capability of the Arctoris approach to drug
discovery. Thanks to our robotic technology platform we can significantly
accelerate the identification of candidates for COVID-19 treatment. By
combining the novel technologies developed by Arctoris and Syntekabio, we aim
to develop potential new treatments faster - for COVID-19 and beyond.”
Sunil Youn MD, Director of Business
Development of Syntekabio, adds:
“Syntekabio is a leader in AI-driven drug discovery. We are pleased to
collaborate with Arctoris, enabling us to rapidly validate our in silico predictions.
Together, we can reach the next drug discovery milestones faster.”
The MoU with Syntekabio is the latest in a
series of partnerships formed by Arctoris this year, which includes publicly
announced partnerships with Insilico Medicine and Molecule.
